A Phase 3 Registration Trial evaluating RZL-012 in China for Submental Fat Reduction
Latest Information Update: 05 Mar 2025
At a glance
- Drugs RZL-012 (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Sponsors Raziel Therapeutics
Most Recent Events
- 05 Mar 2025 New trial record
- 04 Mar 2025 According to Raziel Therapeutics media release, company announces phase 3 study initiation in China for the treatment of fat reduction in the submental area.